GeneDx Holdings Corp. 8-K

What Happened
GeneDx Holdings Corp. announced on June 16, 2026 (effective June 15, 2026) that it appointed Mark Gardner, age 60, as President. Gardner will oversee the company’s laboratory and commercial operations, report to CEO Katherine Stueland, and join the executive leadership team. A press release announcing the appointment was issued the same day.

Key Details

• Base salary: $530,000 per year.
• Target bonus: 65% of base salary.
• Equity: Restricted stock units with a grant-date value of $2,000,000, vesting in equal annual installments over four years, subject to continued service.
• Employment term: Initial three-year term, automatically renewing for successive one-year terms unless earlier terminated.
• Severance/benefits: If terminated without cause or for “good reason” (or the company fails to renew outside a change in control), Gardner receives 9 months’ base salary continuation and 12 months of health coverage (subject to release). If termination occurs within 12 months after a change in control, he would receive 12 months’ base salary, a lump-sum equal to one times his target bonus, 12 months’ health coverage, and accelerated equity vesting (subject to release).
• Background: Most recently Senior VP of Molecular Genomics and Oncology at Quest Diagnostics (Sept 2022–June 2026); prior leadership roles at Corza Medical, OmniSeq, and Thermo Fisher. Education includes US Naval Academy, Georgetown, and Wharton.
• Internal shift: Bryan Dechairo will transition to lead product, technology and innovation initiatives.

Why It Matters
This is a material executive appointment focused on strengthening GeneDx’s laboratory and commercial leadership. Investors should note the immediate impact on operating leadership and the compensation package (notably the $2M equity grant and change‑in‑control protections), which could affect share dilution and executive incentives over the next several years. The filing confirms no related-party or disqualifying transactions and includes a standard indemnification agreement.